Therapy Detail

Therapy Name LGK974
Synonym
Therapy Description

LGK974 binds to and inhibits porcupine (PORCN), resulting in decreased secretion of Wnt ligands and concomitant decrease in Wnt signaling, potentially resulting in reduced cell growth in tumors with dysregulated Wnt signaling (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
LGK974 WNT974 WNT Inhibitor 9 LGK974 binds to and inhibits porcupine (PORCN), resulting in decreased secretion of Wnt ligands and concomitant decrease in Wnt signaling, potentially resulting in reduced cell growth in tumors with dysregulated Wnt signaling (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
NOTCH1 C478F head and neck squamous cell carcinoma sensitive LGK974 Preclinical Actionable In a preclinical study, LGK974 inhibited growth of head and neck squamous cell carcinoma cells harboring NOTCH1 C478F in culture and xenograft models (PMID: 24277854). 24277854
Clinical Trial Phase Therapies Title Recruitment Status
NCT02649530 Phase II LGK974 An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma Withdrawn
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting